Some Considerations on the Design of Population Pharmacokinetic Studies

The goal of this manuscript is to introduce a framework for consideration of designs for population pharmacokinetic orpharmacokinetic–pharmacodynamic studies. A standard one compartment pharmacokinetic model with first-order input and elimination is considered. A series of theoretical designs are considered that explore the influence of optimizing the allocation of sampling times, allocating patients to elementary designs, consideration of sparse sampling and unbalanced designs and also the influence of single vs. multiple dose designs. It was found that what appears to be relatively sparse sampling (less blood samples per patient than the number of fixed effects parameters to estimate) can also be highly informative. Overall, it is evident that exploring the population design space can yield many parsimonious designs that are efficient for parameter estimation and that may not otherwise have been considered without the aid of optimal design theory

[1]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[2]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[4]  Hui C. Kimko,et al.  Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective , 2002 .

[5]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[6]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[7]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  Stephen B. Duffull,et al.  The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..

[9]  Stephen B. Duffull,et al.  Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[13]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[15]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[17]  John Eccleston,et al.  On optimal design for discrimination and estimation , 2004 .